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tion, and is themolecular target of thiazolidinediones (TZDs), insulin sensitizers that enhance glucose utilization
and adipocyte differentiation. However, clinical use of TZDs has been limited by side effects including a higher
risk of fractures and bone loss. Here we demonstrate that the same post-translational modiﬁcations at S112
and S273, which inﬂuence PPARγ pro-adipocytic and insulin sensitizing activities, also determine PPARγ osteo-
blastic (pS112) and osteoclastic (pS273) activities. Treatment of either hyperglycemic or normoglycemic animals
with SR10171, an inverse agonist that blocks pS273 but not pS112, increased trabecular and cortical bone while
normalizing metabolic parameters. Additionally, SR10171 treatment modulated osteocyte, osteoblast, and oste-
oclast activities, and decreased marrow adiposity. These data demonstrate that regulation of bone mass and en-
ergy metabolism shares similar mechanisms suggesting that one pharmacologic agent could be developed to
treat both diabetes and metabolic bone disease.
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Post-translational modiﬁcations1. Introduction
Maintenance of bone mass and quality across a lifetime is a direct
function of bone remodeling. Three types of cells are essential for this
process and their role is coordinated in a highly sequencedmanner. Os-
teoclasts remove old bone, osteoblasts form new bone, and osteocytes
orchestrate this process through production of cytokines including re-
ceptor activator of nuclear factor kappa-B ligand (RANKL), sclerostin
and dickkopf-related protein 1 (DKK1), which balance bone resorption
and formation directly at the remodeling site. Animal studies have shed
light on a close relationship between bone and energy metabolism,
demonstrating that bone remodeling is closely linked to the osteoblastic
response to insulin. Insulin induces osteoblastogenesis and RANKLh Institute, Scripps Florida, 130
oledo Health Science Campus,
eata.leckaczernik@utoledo.edu
. This is an open access article underproduction leading to high bone mass that is associated with increased
bone turnover (Fulzele et al., 2010, Ferron et al., 2010). In contrast, in
models of insulin resistance, induced by either high-fat diet feeding or
genetic manipulation, bone turnover is decreased (Wei et al., 2014,
Lecka-Czernik et al., 2015).
Numerous epidemiologic studies have shown that skeletal fragility
in individuals with Type 2 diabetes (T2D) is increased at least 2-fold de-
spite normal or high bone mineral density (BMD) and greater body
mass index (BMI), the factors which are considered protective for
most fractures in non-diabetic adults. The lack of the association be-
tween higher BMD and lower incidence of fractures indicates that in
T2D bone biomechanical properties are compromised. Indeed, diabetic
bone, particularly in the appendicular skeleton, has a number of struc-
tural characteristics which predispose to fractures, including greater
cortical porosity, smaller cortical area, decreased bone material
strength, and high bone marrow adiposity (Lecka-Czernik and Rosen,
2015).
Histomorphometric studies in humans indicate that bone turnover
in older T2D patients is compromised, which may result in higher
BMD but decreased bone quality (Krakauer et al., 1995). Furthermore,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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markers, higher levels of sclerostin, a negative regulator of bone forma-
tion, and lower numbers of circulating osteoprogenitors. Moreover,
highly reactive glucose metabolites (AGEs) are increased in T2D. These
may impact bone ‘quality’ by slowing bone turnover and increasing
bone stiffness and fragility through aberrant cross-links between colla-
gen ﬁbers (Lecka-Czernik and Rosen, 2015).
Skeletal homeostasis is linked to insulin sensitivity through the nu-
clear receptor PPARγ. PPARγ regulates lineage commitment of mesen-
chymal cells toward osteoblasts and adipocytes, and recruitment of
osteoclasts from a pool of hematopoietic cells. Activation of PPARγ
with the full agonist rosiglitazone suppresses osteoblastogenesis and in-
duces adipocyte differentiation. This results in decreased bone forma-
tion and accumulation of adipocytes in the marrow cavity (Lazarenko
et al., 2007). PPARγ activation also supports osteoclast differentiation
through direct and indirect mechanisms. In monocytes, rosiglitazone
stimulates osteoclast differentiation through a PPARγ coactivator 1-
beta (PGC-1β)-dependent mechanism, while in mesenchymal cells it
increases support for osteoclastogenesis by stimulating RANKL produc-
tion (Wei et al., 2010, Lazarenko et al., 2007).
Thiazolidinediones (TZDs), full agonists of PPARγ, have consis-
tently afforded robust efﬁcacy for treatment of T2D. However, safety
concerns including bone loss and increased fracture rates, particular-
ly in postmenopausal women (Kahn et al., 2008), have restricted
their use in T2D. Previously we demonstrated that the insulin
sensitization provided by full and partial PPARγ agonists correlates
with the ability of these drugs to block phosphorylation of PPARγ
at serine 273 (pS273) (Choi et al., 2010), and that PPARγ anti-
osteoblastic and insulin-sensitizing activity can be separated using
selective modulators which block pS273 but have no activity toward
phosphorylated serine 112 (pS112) (Kolli et al., 2014). Recently, we
reported that the PPARγ inverse agonist SR2595 promoted
osteoblastogenesis when tested in cultured human mesenchymal
stem cells (MSCs) (Marciano et al., 2015). Synthetic optimization
led to the identiﬁcation of 2-phenoxy propanoic acids that exhibited
superior pharmacokinetic properties over compounds in the
biphenyl-2-carboxylic acid series (e.g., SR1664 and SR2595).
Here, we demonstrate that optimized 2-phenoxy propanoic acid
modulator SR10171, with inverse agonist activity (repression of target
gene expression) for PPARγ and modest agonist activity (activation of
target gene expression) for PPARα, increases bone mass by increasing
bone formation and bone turnover; two processes affected in diabetic
bone. We show that SR10171 targets osteoblast, osteocytes, and osteo-
clasts through mechanisms overlapping those regulating whole body
energy metabolism. We demonstrate that the same posttranscriptional
modiﬁcations (PTMs) which determine adipocytic (pS112) and insulin
sensitizing (pS112) activities also determine PPARγ osteoblastic and os-
teoclastic activities, respectively. The elucidation of such overlap is a
prerequisite for development of efﬁcient anti-diabetic therapy that
will simultaneously treat diabetic bone disease.
2. Material and methods
2.1. Animal experiments
C57BL/6 mice, 12 week old males, were purchased from the Jackson
Laboratories (Bar Harbor, ME). The animal treatment and care protocols
conformed to the NIH Guidelines and were performed under theTable 1
Characteristics of SR10171 and rosiglitazone.
Compound IC50 (nM)a PPARγ EC50 (nM) PPARγ GAL-4 EC50 (nM) PPARγ PPRE
Rosiglitazone 18 7.4 (100%) 10
SR10171 220 7260 (4%) Inverse agonist
a LanthaScreen; IC50 — half maximal inhibitory concentration; EC50 — half maximal effectiveUniversity of Toledo Health Science Campus Institutional Animal Care
and Utilization Committee protocol.2.1.1. Lean mice experiment
Animals were fed for 8 weeks either non-supplemented regular diet
(RD) providing 12 kcal% from fat (2016 Teklad Global, Harlan Laborato-
ries, Indianapolis, IN)., or RD supplemented with either rosiglitazone or
SR10171 at the dose of 15mg/kg/d of each drug (n=5 per group). This
dose of rosiglitazone and duration of treatment was previously
established as decreasing bone mass by 20%. The matching dose of
SR10171 was calculated based on the following reasoning. SR10171
binding afﬁnity to PPARγ is 10-fold lower and S273 phosphorylation
blocking activity is 50% lower than rosiglitazone (Table 1). This together
with 2.5-fold higher than rosiglitazone retention levels in plasma of an-
imals treated for 4 days (Table 2) resulted in the decision to treat ani-
mals with the same dose of each drug. Food intake was monitored
during the entire experiment to calculate an ingested dose of SR10171
(12.7 mg/kg/d) and rosiglitazone (11.7 mg/kg/d).2.1.2. DIO mice experiment
Animals were fed ad libitum for 11weeks high fat diet (HFD) provid-
ing 45 kcal% from fat (D12451; Research Diets, New Brunswick, NJ) to
develop diet induced obesity (DIO). DIOmicewere randomized accord-
ing to body weight and were separated into three groups (n = 7 per
group) and fed for 4 weeks as follows: HFD (control), HFD supplement-
ed with rosiglitazone at the dose 25 mg/kg/d, and HFD supplemented
with SR10171 at the dose 25mg/kg/d. The dose of each drug for this ex-
periment was decided based on our experience that a dose of
rosiglitazone between 20 and 25 mg/kg/day administered for 4 weeks
to DIO animals results in signiﬁcant loss of trabecular bone in both,
axial and appendicular skeleton (Kolli et al., 2014). Ingested doses of
SR10171 (22.1 mg/kg/d) and rosiglitazone (24.2 mg/kg/d) were calcu-
lated at the end of treatment based on food intake monitored through-
out duration of entire experiment. In parallel, a group of sex- and age-
matched control (n= 4) was fed RD. Testing of metabolic parameters
is described in the Supplemental data.2.2. Bone analysis using microCT and histomorphometry
Details of methods to measure bone and marrow fat using mCT and
static and dynamic histomorphometry are described in the Supplemental
data.2.3. Cell culture experiments
MLO-A5 cells represent an osteocytic cell line (gift from Dr.
Bonewald, University of Missouri, Kansas City, MO), AD2 and U33 cells
represent spontaneously immortalized marrow pre-adipocytes and
pre-osteoblasts, respectively, whereas U33/γ2 cells represent U33 cells
stably transfected with PPARγ2 expression construct, and were previ-
ously described (Lecka-Czernik et al., 1999). RAW264.7 cells represent-
ed a murine monocyte/macrophage cell line. Cell cultures,
differentiation assays, gene silencing using lentiviral infection with
shRNA speciﬁc for PPARγ or PPARα, and gene expression analysis
using real time PCR are described in detail in the Supplemental data.% inhibition S273pPPARγ (20 μM) IC50 (μM)a PPARα EC50 (μM) PPARα GAL-4
100 No binding No activity
54 1.1 1.5
concentration.
Table 2
Plasma levels of SR10171 and rosiglitazone at the end of experiments.
Treatment Plasma levels
SR10171
(μM)
Rosi
(μM)
C57BL6 on RD
4 days treatment: SR10171 – 5 mg/kg/d; Rosi – 5 mg/kg/d
4.01 1.67
DIO model on HFD
4 wks treatment: SR10171 – 22.1 mg/kg/d; Rosi – 24.2 mg/kg/d
14.25 0.10
C57BL/6 on RD
8 wks treatment: SR10171 – 12.7 mg/kg/d; Rosi – 11.7 mg/kg/d
15.97 6.28
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AD2cells representingmarrowpreadipocyteswere pre-treatedwith
vehicle, 1 μM rosiglitazone, or 5 μM SR10171 for 1 h followed by treat-
ment with 50 ng/ml TNF-α for 1 h followed by Western blot analysis
for pS273 and pS112 of PPARγ (Choi et al., 2010). Details are in the Sup-
plemental data.
2.5. Extraction of osteoblast- and osteocyte-enriched fractions
Cell fractions enriched in either osteoblasts or osteocytes were iso-
lated by sequential collagenase digestion of fresh femora bone, accord-
ing to a previously described protocol (Kramer et al., 2010), and
immediately lysed for analysis of gene expression.
2.6. Analysis of SR10171 and SR9525 pharmacology
Methods for the LanthaScreen TR-FRET Competitive Binding Assay,
hydrogen/deuterium exchange mass spectrometry (HDX-MS), NR box
peptide interaction assay, and in silico docking are described in detail
in the Supplemental data.
2.7. Statistical analysis
Data are presented as the means ± SD and were analyzed by One
Way Anova using statistical software package of SigmaPlot (version
13.0). P value less than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. pS112 and pS273 determine PPARγ skeletal activities
PPARγpro-adipogenic and insulin sensitizing activities in cells ofmes-
enchymal lineage correlate respectively with the phosphorylation status
of serines S112 and S273 (Hinds et al., 2011, Choi et al., 2011). To test
whether these PTMs correlate with PPARγ osteoblastic and osteoclastic
activities we transfected cells of either osteoblastic lineage (U33 cells)
or osteoclastic lineage (RAW264.7) withmutated PPARγ expression con-
structs in which phosphorylation at either S112 (S112A mutant) or S273
(S273Amutant) was blocked. As shown in Fig. 1a, in U33 cells S112A but
not S273A mutation decreased extracellular matrix mineralization and
expression of runt-related transcription factor 2 (Runx2) and osterix
(Osx), and increased expression of Dkk1, an inhibitor of Wnt signaling
pathway. Thus, induction of adipocytic differentiation with PPARγ de-
phosphorylated at S112 simultaneously suppresses osteoblastic pheno-
type, perhaps as a result of reciprocal relationship between PPARγ and
RUNX2 activities (Ge et al., 2016). In contrast, blocking phosphorylation
at S273 increased PPARγ pro-osteoclastic activity in RAW264.7 cells
(Fig. 1b) including increased number of TRAP+ multinucleated osteo-
clasts and expression of c-Fos and catepsin K (Ctsk)markers ofmaturating
osteoclasts (Fig. 1b). In addition, blocking phosphorylation at S273 in-
creases support for osteoclastogenesis by increasing Rankl and decreasing
osteoprotegerin (Opg) expression in mesenchymal U33 cells (Fig. 1a).Thus, PPARγ anti-osteoblastic action requires blocking the same PTM as
is required for adipogenesis, whereas pro-osteoclastic action requires
blocking the PTM as is required for insulin-sensitizing activity.
We then examined whether these activities can be manipulated
pharmacologically. SR10171 compound (Fig. 1c) is an optimized analog
of SR1664 (Choi et al., 2011) which demonstrates high-afﬁnity binding
to PPARγ and unlike SR1664, exhibits partial inverse agonism of PPRE-
mediated transcriptional activity (Table 1) and demonstrates modest
PPARα agonist activity (EC50 = 1.5 μM). The structure activity relation-
ship (SAR) of SR10171 is consistent with other examples from this
chemical series (Asteian et al., 2015,Marciano et al., 2015). Importantly,
SR10171 effectively blocks phosphorylation of S273 (pS273), which has
been shown to correlatewith PPARγ insulin sensitizing activity; howev-
er, in contrast to full agonist rosiglitazone, SR10171 inverse agonism ac-
tively suppresses PPARγ basal transcriptional activity (Table 1).
As shown in Fig. 1d and e, both SR10171 and rosiglitazone block
phosphorylation of S273, yet only rosiglitazone alters phosphorylation
of S112. Next, we investigated whether SR10171 changes marrow
MSC allocation toward osteoblast and adipocyte lineage. Consistent
with inverse agonist activity, SR10171 decreased basal expression of
fatty acid binding protein 4 (Fabp4) and adiponectin (Adipoq) in mar-
rowMSC culture, while the full agonist rosiglitazone increased their ex-
pression substantially (Fig. 1f). This correlated with the expected
changes in transcriptional activity of PPARγ, as measured in a reporter
gene assay (Fig. 1f). A combination of a colony forming units of osteo-
blasts (CFU-OB) assay and expression levels of osteoblast-speciﬁc
gene markers in primary bone marrow cultures demonstrated that
SR10171 treatment did not alter MSC commitment toward the osteo-
blast lineage, while rosiglitazone attenuated CFU-OB formation and ex-
pression of osteoblast-speciﬁc gene markers (Fig. 1g and h).
Results from an assay for osteoclast differentiation from a pool of
non-adherant hematopoietic stem cells (HSCs) conﬁrmed that both
SR10171 and rosiglitazone induce pro-osteoclastic activity of PPARγ
where treatment with either compound increased the number of
multi-nucleated TRAP-positive osteoclast-like cells ex vivo and in-
creased expression of c-Fos and Ctsk (Fig. 1i and j). These observations
were consistent with PTM status and suggest that the mechanism by
which PPARγ increases osteoclast differentiation from a pool of HSCs
is different than PPRE-mediated transcriptional activity regulating adi-
pocyte/osteoblast differentiation from MSCs.
3.2. Pharmacological repression of PPARγ is anabolic for bone
Given that the full agonists rosiglitazone and pioglitazone decrease
bone mass and increase marrow adiposity, and inverse agonists
(Marciano et al., 2015) suppress adipogenesis and promote osteogenesis
in vitro, we sought to determine if the above ﬁndings can be recapitulated
in vivo following chronic administration in mice. SR10171was chosen for
testing in long-term bone studies due to its excellent pharmacokinetic
properties enabling formulation in feed to facilitate chronic daily admin-
istration of drug coupled with its unique pharmacological proﬁle com-
pared to SR2595. While both SR2595 and SR10171 (Fig. S1a) are inverse
agonists that suppress PPARγ transcriptional activity (Fig. S1b), they dis-
play subtle differences in their binding poses (Fig. S1c), distinct conforma-
tional dynamics as determined by HDX (Fig. S1d), and differential afﬁnity
for peptides containingNRboxbindingmotifs derived fromtranscription-
al coregulators (Fig. S1e). These distinct molecular interactions result in
different effects on RUNX2 activity (Fig. S1f) and expression of markers
of Wnt and BMP signaling pathways activity (Fig. S1g).
To test the longitudinal effects of SR10171 administration on the
skeleton of lean, normoglycemic C57BL/6 mice were treated with com-
pound at a dose of 15 mg/kg/d for 8 weeks. Rosiglitazone treated ani-
mals (15 mg/kg/d) served as a control of PPARγ-mediated metabolic
and skeletal effects. The dose of each drug used in these studies was
based on compilation of SR10171 and rosiglitazone pharmacokinetics,
binding afﬁnities, and activities toward blocking of PPARγ pS273. After
Fig. 1.Effect of pS112 andpS273 of PPARγ on adipocyte, osteoblast and osteoclast differentiation. (a) The effect of S112A andS273Amutations onosteoblast differentiation.U-33 cellswere
transfected with either WT or mutated PPARγ expression constructs and grown in pro-osteoblastic conditions followed by measurement of extracellular calcium or RNA isolation.
(b) Effect of PPARγ S112A and S273A mutations on osteoclast differentiation. RAW264.7 was transfected with either WT or mutated PPARγ expression constructs followed by culture
in medium supplemented with 50 ng/ml M-CSF and 50 ng/ml RANKL for 4 days, then either stained for TRAP expression (left panel) or RNA was isolated for analysis of gene
expression (right panel). (c) Chemical structure of SR10171 ((S)-2-(3-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-
methylpropanoic acid) and rosiglitazone ((RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione). (d) The effect of SR10171 and rosiglitazone on blocking of
S273 phosphorylation in AD2 cells. (e) The effect of ligands on blocking of S112 phosphorylation in AD2 cells. Protein levels quantiﬁcation was performed using Image J software and
displayed as graphs below Western blot renderings. (f)–(j) cell treatment consisted of 10 μM SR10171 (71), or 1 μM rosiglitazone (R), or DMSO as vehicle control (V). (f) Left and
middle panels — the effect on adipocyte-speciﬁc gene marker expression in marrow MSCs treated for 6 days, as above. Right panel — the effect on transcriptional activity of PPARγ
measured in U33/γ2 cells transfected with PPRE promoter construct and treated for 24 h. (g) Osteoblast differentiation as measured in CFU-OB assay. (h) Expression of osteoblast-
speciﬁc gene markers in marrow MSCs. (i) The effect on osteoclast differentiation. Non-adherant bone marrow cells were cultured as described in experimental procedures. TRAP+
multinucleated cells (N4 nuclei) were enumerated and average calculated from triplicates. (j) Expression of osteoclasts gene markers in cultures described in (i). Data represent the
mean ± SD (n= 3–6 experiments). *P b 0.05; **P b 0.01; ***P b 0.001 One Way Anova.
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on bone. Trabecular bone mass in proximal tibia was increased by 26%
as compared to non-treated controls mainly due to increased number
of trabeculae (Fig. 2a). As expected, rosiglitazone decreased trabecularbone mass by decreasing trabeculae thickness. Bone formation was
markedly increased in the proximal tibia of mice receiving SR10171.
Histomorphometric measurements conﬁrmed that an increase in bone
mass with SR10171 was due to an increase in mineral apposition rate
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between two calcein-labeled osteoid layers (Fig. 2b), and from an in-
creased number of osteoblasts (Fig. 2c). As expected, rosiglitazone at-
tenuated MAR and BFR and decreased the number of osteoblasts.
Interestingly, both compounds increased the number of osteoclasts
(Fig. 2c). The calculated ratio of osteoblasts to osteoclasts was 2.5 for
control, 1.4 for rosiglitazone and 2.8 for SR10171 indicating higher
bone formation for SR10171 and higher resorption for rosiglitazone, as
compared to control (Fig. 2c). SR10171, consistent with its inverse ago-
nist activity, decreased the number of marrow adipocytes by 50%,
whereas full agonist rosiglitazone increased adipocyte number by 5-
fold (Fig. 2c). Combined, these results indicate that the increased trabec-
ular bone mass in lean animals receiving SR10171 resulted from high
bone formation associated with increased bone turnover, whereas
bone loss in animals receiving rosiglitazone resulted from suppressed
bone formation and increased bone resorption.
Next we tested the efﬁcacy of SR10171 in mice with diet-induced
obesity (DIO) and impaired glucose tolerance. Mice were administered
either high fat chow, or the same chow supplemented with either
SR10171 or rosiglitazone at the dose of 25 mg/kg/d for 4 weeks. The
dosewas increased as the duration of treatmentwas decreased; howev-
er, similar effects onmetabolic parameters as described belowwere ob-
served with dose as low as 5 mg/kg given once-a-day orally (data not
shown). SR10171 normalized glucose tolerance in DIO animals to the
samedegree as rosiglitazone (Fig. 2d). SR10171 increased both bone tis-
sue volume and trabecular bone mass, as well as both MAR and BFR
(Fig. 2e and f). For marrow adiposity, the effect of SR10171 resulted in
almost 5-fold decrease in fat volume, while fat volume in the tibia of
mice treated with rosiglitazone increased almost 100-fold, as compared
to no drug control animals (Fig. 2g). Not surprisingly, rosiglitazone
caused signiﬁcant bone loss across all bone sites and was associated
with high volumes of marrow adipose tissue, during regular and high
fat diets, whereas SR10171 had a positive effect on the appendicular
skeleton but was neutral for the axial skeleton and showed virtually
no marrow adiposity at either site (Fig. S2a, Table S1).
Positive effects on cortical bone mass were also observed following
SR10171 treatment. Calcein labeling of the periosteal surface of the
midshaft tibia in both lean and DIO animals was increased, as compared
to control mice (Fig. 2h and i). Accordingly, in both models the labeled
surface of periosteum was larger in bone of animals that received
SR10171, and the labeling wasmore intense. In lean SR10171 treated an-
imals in which periosteal labeling was only 1.5 times larger than in the
control (Fig. 2h), the cortical area was not affected (Fig. S2b). However,
in DIOmice the periosteal labeling was 9 times larger in SR10171 treated
than in control, which had almost completely attenuated periosteal activ-
ity (Fig. 2i). This increase in activity correlatedwith increased cortical area
(Fig. S2b). SR10171 also increased osteocyte lacunae density in cortical
bone of both models providing further evidence of increased bone turn-
over induced by this compound (Fig. 2h and i). Analysis of the organiza-
tion of collagen ﬁbers by second-harmonic generation confocal
microscopy showed a highly organized ﬁber structure in bone adjacent
to mineralization zone of the periosteum (Fig. S3) indicating that a
newly formed bone is of normal structure. The beneﬁcial effect of
SR10171 on bone was also reﬂected in changes in cortical tissue mineral
density (TMD, mg HA/cm3) (control: 954.6 ± 17.6; rosiglitazone:Fig. 2. Effect of SR10171 and rosiglitazone on trabecular and cortical bone of lean and DIO C5
renderings (upper panels) and measurements of trabecular parameters. Bar — 0.1 mm. (b)
entire proximal tibia labeled with calcein (upper panels) (magniﬁcation 5×; bar — 0.2 mm
0.02 mm). Quantiﬁcation of mineral apposition rate (MAR) and bone formation rate (BFR) (low
per bone perimeter (N.Oc/B.Pm), osteoblasts to osteoclasts ratio (N.Ob/N.Oc), and number of
end of experiment. (e)–(f) Analysis of trabecular bone in tibia of DIO mice. (e) mCT measure
with calcein. (g) mCT renderings of fat stained with osmium tetroxide (left panels, fat appea
bone of lean animals. (i) Cortical bone of DIO animals. Representative microphotographs of c
bar — 0.2 mm), histomorphometry of labeled periosteal bone perimeter (MS/BS) and osteocyt
mass; Tb.N— trabecular number; Tb.Th — trabecular thickness. Data represent the mean ± SD954.5 ± 17.9; SR10171: 978.6 ± 10.4, P b 0.05 vs. control and
rosiglitazone).
3.3. Treatment of DIO mice with SR10171 normalizes energy metabolism
Even though SR10171 and rosiglitazone exhibited the same actions
on glucose tolerance (Fig. 2d), these compounds had contrasting effects
on body weight, fat content, and energy metabolism. SR10171 de-
creased body weight in DIO mice maintained on HFD, as compared to
controls or rosiglitazone-treated group on the same diet, and had no im-
pact on body weight in lean animals (Fig. 3a and b). Interestingly, the
decrease in body weight in DIO mice was observed as early as one
week after initiation of SR10171 treatment, and was stabilized to the
level of control animals two weeks post dosing. Food intake was not af-
fected indicating that both administered drugs did not cause taste aver-
sion (Fig. S4a). The observed decrease in the body mass in SR10171
treated DIO mice was accompanied by a decrease in fat content
(Fig. S4b), and whole body composition measured as lean/fat ratio
was similar to mice fed regular chow (Fig. S4b). Finally, SR10171 treat-
ment resulted in a decrease in the mass of both epididymal white adi-
pose tissue (eWAT) and interscapular brown adipose tissue (iBAT) in
obese mice (Fig. S4c).
Changes in body composition in SR10171 treated DIO mice
corresponded to increased energy expenditure. Oxygen consumption,
carbon dioxide release, calculated respiratory exchange ratio (RER), heat
production and locomotion were signiﬁcantly higher in DIO mice receiv-
ing SR10171, as compared to control and rosiglitazone-treated group
(Fig. 3c, Tables S2 and S3). Treatmentwith SR10171 increased the expres-
sion of adiponectin and fatty acid transporter FABP4 in eWAT of DIOmice
to that observed in age-matched lean controls (Fig. 3d), and normalized
the expression of regulators of futile metabolism in adipocytes (forkhead
box protein C2 (FoxC2) and bone morphogenic protein 4 (Bmp4)), and
beige fatmarkers (T-box transcription factor 1 (Tbx1) andhomeobox pro-
tein C9 (HoxC9)). That was accompanied with a modest increase in
uncoupling protein 1 (Ucp1) expression (Fig. 3d).
Consistent with no effect on body weight in lean animals (Fig. 3b),
SR10171 had no impact on body composition (not shown) and had no
effect on eWAT weight; however, a modest decrease in the weight of
iBAT was observed (Fig. S4d). In lean animals, indirect respiratory calo-
rimetry showed no effect of SR10171 on any measured parameter,
while rosiglitazone increased respiration and heat production indicat-
ing active modulation of metabolism even in non-pathologic conditions
(Fig. 3e, Tables S2 and S3). Consequently, in lean non-diabetic mice,
SR10171 afforded only a modest decrease in expression of Fabp4 and
Ucp1whereas rosiglitazone increased the expression of Adipoq, Fabp4,
Bmp4, HoxC9, and Ucp1 (Fig. 3f). Thus, the normalizing effect of
SR10171 under conditions of impaired energy metabolism (obesity)
and the neutral effect in conditions of efﬁcient energy metabolism
(lean) suggest that SR10171modulates metabolism in an “on-demand”
manner to which increased insulin sensitivity may contribute.
3.4. PPARγ and PPARα regulate osteocyte activities
Since SR10171 increased bone formation and osteoblast number in
animals (Fig. 2) butwas neutral for osteoblast differentiation in cultured7BL/6 mice. (a)–(c) Analysis of trabecular bone in proximal tibia of lean mice. (a) mCT
Dynamic histomorphometry of bone double-labeled with calcein. Microphotographs of
) and bone surface labeled with calcein (lower left panels) (magniﬁcation 40×; bar —
er right panels). (c) Number of osteoblasts per bone perimeter (N.Ob/B.Pm), osteoclasts
adipocytes (N.Ad) per region of interest (ROI). (d) Glucose tolerance in DIO mice at the
ments of trabecular parameters. (f) MAR and BFR quantiﬁed from bone double-labeled
rs as yellow, bar — 1.0 mm) and its volumetric quantiﬁcation (right panel). (h) Cortical
alcein-labeled endosteal and periosteal bone surface (upper panels) (magniﬁcation 5×;
e lacunae density (lower panels). TV — tissue volume; BV — bone volume; BV/TV — bone
(n= 3–7 per group). *P b 0.05; **P b 0.01; ***P b 0.001 One Way Anova.
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and osteocytes freshly-isolated from femora of treated animals. Isolated
cell populations reﬂect the status of osteoblasts and osteocytes at the
time of animal sacriﬁce as it is analyzed immediately after liberation
from either endosteal bone surface (fraction 3, OB) or cortical mineral-
ized matrix (fraction 6, OT). The enrichment of each fraction was
assessed by comparing levels of expression of genes known to be
more abundantly expressed in either osteoblasts (Osx and Ibsp) or oste-
ocytes (Dmp1, Sost, Rankl,Dkk1, E11, and FGF23).As shown in Fig. S5, the
expression level of cell type speciﬁc markers was 3–100 folds different
between OB and OT fractions, thus providing reassurance of high en-
richment. In the osteoblast fraction isolated from SR10171-treated
lean animals, the expression of Osx and matrix extracellular
phosphoglycoprotein regulating phosphatemetabolism (Mepe),was in-
creased indicating that osteoblasts were highly activated (Fig. 4a).
Previously it has been shown that networks of signaling pathways
regulate the activity of osteoblasts. TheWnts and BMPs are the predom-
inant ligands for local autocrine/paracrine effects in bone, including
control of Osx andMepe expression (Cho et al., 2012; Tan et al., 2014).
Indeed, osteoblasts from SR10171-treated animals showed increased
expression of Wnt10b ligand and decreased expression of Axin2, a
member ofβ-catenin degradation complex, but no change in expression
of BMP ligands (Fig. 4a). In contrast, osteoblasts from rosiglitazone-
treated animals have an opposite pattern of these gene expression con-
sistent with suppressive effect onWnt and BMP signaling activities and
osteoblastogenesis (Shockley et al., 2009). Results from a luciferase re-
porter gene assayusing Top-Flash construct conﬁrmed that SR10171 ac-
tivated β-catenin transcriptional activity, whereas rosiglitazone
decreased it (Fig. 4b). Paradoxically, SR10171 decreased Opg expression
which is positively regulated by the canonical Wnt pathway and con-
tributes to the anti-osteoclastic effect of this network (Fig. 4a). Regard-
less, as shown in Fig. 1a, Opg expression is directly dependent on pS273,
the same PPARγ PTM which regulates osteoclastogenesis and RANKL
expression and insulin sensitivity. Recently it was demonstrated that pi-
oglitazone (a TZD) had a negative effect on Opg expression (Avtanski
et al., 2016) supporting the conclusion that PPARγ is dominant over
the Wnt pathway with respect to regulation of this network. Although
both compounds have pro-osteoclastic effect and both decreased Opg
expression, it is interesting that only rosiglitazone decreased expression
ofWnt16 (Fig. 4a). Wnt16 was recently identiﬁed as a negative regula-
tor of resorption in cortical bone (Moverare-Skrtic et al., 2014) and a
positive regulator of periosteal bone formation (Wergedal et al.,
2015). Thus, SR10171 and rosiglitazone exhibit differential regulation
ofWnt16 expression which in turn may contribute to their different ef-
fects on cortical bone (Fig. 2h and i; Fig. S2b).
Osteoblasts activity is regulated by the secretory action of osteo-
cytes, including sclerostin, encoded by the Sost gene, andDKK1 proteins,
which antagonizeWnt pathway activity by binding to LRP5/6 receptors
(Baron and Kneissel, 2013). Consistent with higher osteoblasts function
with increased bone formation rates, Sost andDkk1 expressionwere de-
creased in osteocytes of animals receiving SR10171 (Fig. 4c). In contrast,
Sost expression was unaffected and Dkk1 was increased in osteocytes
derived from animals receiving rosiglitazone. Osteocytes also regulate
bone resorption by producing RANKL (Xiong et al., 2011). Both com-
pounds increased expression of Rankl in osteocytes (Fig. 4c). This to-
gether with decreased Opg expression in endosteal osteoblasts
correlatedwith a greater number of osteoclasts in vivo in bone of treatedFig. 3.Effect of SR10171 and rosiglitazone on fat andmetabolic parameters ofDIO and leanC57B
feeding medicated diet for the next 4 weeks. Arrow indicates start of administration of medi
(b) Body weight of lean animals at the end of an 8 week feeding medicated diet. (c) Calorimet
plots show measurements made every 20 min within 24 h period, whereas bar plots show
oxygen consumption (ml/h/kg); VCO2 — carbon dioxide production (ml/h/kg); RER — respira
mice. (e) Calorimetric measurements of respiratory parameters in lean mice at the end of exp
represent the mean ± SD (n= 4–5 per group). *P b 0.05; **P b 0.01; ***P b 0.001 One Way Ananimals (Fig. 2c). Thus, in contrast to the opposing effects of SR10171
and rosiglitazone on osteoblast and osteocyte function that support
bone formation both compounds positively regulate osteoclast differen-
tiation via two mechanisms, one consisting of enhanced hematopoietic
osteoclastogenic differentiation and the other modifying mesenchymal
cell support for osteoclast differentiation.
To address the questionwhether Sost,Dkk1, and Rankl transcriptions
are directly regulated by PPARs in osteocytes, the expression level of
each gene was measured in primary osteocytes treated ex vivo with
SR10171, rosiglitazone, and WY14643 which is a PPARα full agonist.
As expected, SR10171 decreased the expression of Sost and Dkk1,
whereas rosiglitazone not only increased expression of Dkk1, but also
Sost, which was not observed in vivo (Fig. 4d). In contrast to the effect
on Rankl expression in vivo, when applied directly on primary osteo-
cytes SR10171 did not increase its expression, while rosiglitazone had
a sustained positive effect (Fig. 4d). Treatment with WY14643 de-
creased expression of Sost, but did not have an effect on expression of
Dkk1 and Rankl (Fig. 4d). To analyze which actions of SR10171 in oste-
ocytes are mediated through PPARγ or PPARα, we knocked-down
(KD) the expression of each receptor separately in MLO-A5 cells using
lentiviral delivery of PPAR-speciﬁc shRNA. Decrease in PPARα protein
levels by 65% (Fig. 4e) resulted in a 5-fold increase in basal Sost expres-
sion (Fig. 4f), while a 50% decrease in PPARγ protein levels had no effect
suggesting that Sost is under negative control of PPARα. In contrast,
PPARγ KD, but not PPARα, abrogated Dkk1 expression (Fig. 4f) suggest-
ing thatDkk1 is under positive control of PPARγ. In conclusion, SR10171
regulates osteocyte activities via combined effects on PPARγ and
PPARα.
4. Discussion
Currently there are nodrugs that prevent insulin resistance resulting
fromdiet-induced obesitywhile simultaneously being anabolic for bone
despite the need for such agents to combat the ongoing epidemic of T2D
and its deleterious effect on the skeleton. Approved agents that are used
to help control obesity and insulin sensitization are either neutral on
bone or more troublesome and have negative effects on the skeleton.
Drugs that enhance sympathetic outﬂow and thereby reduce obesity
by increasing energy expenditure cause bone loss by uncoupling forma-
tion from resorption (Motyl et al., 2015). The TZDs which are robust in-
sulin sensitizers, cause bone loss in mice and result in increased risk for
fractures in humans (Kahn et al., 2008). SGLT2 inhibitors effectively
control plasma glucose levels, but negatively affect bone by altering cal-
cium and phosphate homeostasis (Taylor et al., 2015). Underlying the
negative side effects of these therapies is the increased bone fragility
typical in T2D patients that is associated with decreased bone mechan-
ical properties caused by impaired bone turnover (Lecka-Czernik and
Rosen, 2015). Drugs which restore coupled bone remodeling and that
simultaneously restore insulin sensitivity would be ideal.
Here we present compelling evidence that polypharmacological
modulation of both PPARγ (repression) and PPARα (mild activation)
with SR10171, a prototype chemical probe which fulﬁlls the “one
drug, multiple targets” concept, is anabolic for bone independent of its
insulin sensitizing activity as supported by the following observations.
First, we demonstrated that the same PTMs that determine adipocytic
and insulin sensitizing properties, also deﬁne PPARγ osteoblastic and
osteoclastic activities. We showed that a reduction in pS273 correlatedL/6mice. (a) Bodyweight change in animals fedHFDandRD for 8weeks before initiation of
cated diet. Asterisks indicate signiﬁcant differences between control RD and HFD + 71.
ric measurements of respiratory parameters in DIO mice at the end of experiment. Linear
average of measurements collected during either 12 h light or 12 h dark period. VO2 —
tory exchange ratio. (d) Gene expression analysis of adipocytic markers in eWAT of DIO
eriment. (f) Gene expression analysis of adipocytic markers in eWAT of lean mice. Data
ova.
Fig. 4. PPARγ and PPARα activities regulate osteoblast and osteocyte functions. (a) Relative mRNA expression of gene markers in isolated osteoblasts from femora endosteal surface.
(b) The effect of SR10171 and rosiglitazone on transcriptional activity of TCF/LIF/β-catenin complex measured in U33/γ2 cells transfected with Top-Flash promoter construct and
treated for 72 h with tested ligands. (c) Relative mRNA expression of gene markers in isolated osteocytes from femora cortical bone. Expression of Dmp1, E11, and Fgf23, served as a
purity control of osteocyte isolates and conﬁrmed equivalent enrichment in all samples analyzed. (d) Relative mRNA expression of Sost, Dkk1, and Rankl in primary osteocytes treated
with either 10 μM SR10171, or 1 μM rosiglitazone, or 50 μMWY14643 in ex vivo conditions for 3 days. (e) Protein levels after shRNA knocked-down (KD) of either PPARα or PPARγ.
KD was introduced in MLO-A5 cells using lentiviral shRNA constructs. Protein levels of either PPARγ or PPARα were assessed by Western blots, quantitated and normalized to the
levels of HSP90, a housekeeping protein. (f) The effect of PPARγ (γKD) or PPARα (αKD) silencing on Sost and Dkk1 gene expression. Data represent the mean ± SD (n= 3 per group,
repeated twice). *P b 0.05; **P b 0.01; ***P b 0.001 One Way Anova.
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osteoblastic activity. Importantly, we demonstrated that the same
PTM at S273 regulates both osteoclast differentiation from a pool of he-
matopoietic cells, and mesenchymal cell support by regulating RANKL
and OPG expression. Since SR10171 reduced pS273, it simultaneously
enhanced insulin sensitivity while increasing osteoclastogenesis. In
contrast to rosiglitazone, SR10171 did not reduce pS112, blocked adipo-
genesis and increased β-catenin and RUNX2 transcriptional activity
when acting directly on cells of the mesenchymal lineage. Therefore,
SR10171 can be categorized as an agonist for insulin sensitizing and
bone resorbing activities, and an inverse agonist for adipocytic and
bone forming activities. The phenotype of mice treated with SR10171
was one of insulin sensitization and increased bone turnover. Although
bone resorptionwas increasedwith SR10171, therewas no break on os-
teoblastogenesis, hence coupling was restored within the bone remod-
eling unit as formation was maintained in spite of higher turnover.
Second, we demonstrated that two members of the PPAR subfamily
regulate osteocytic activity that in turn supports bone formation and
bone turnover. SR10171 was shown to target PPARγ and/or PPARα in
osteocytes, which results in decreased expression of two inhibitors of
Wnt signaling, DKK1 and sclerostin, while increasing RANKL. This
would result in increased bone turnover with the balance shifted to-
ward bone formation. Indeed, high expression of Osterix and Mepe in
endosteal osteoblasts, and the lack of an SR10171 effect on these tran-
script levels in vitro, suggest an overall increase in osteocyte activity.
Considering that the expression of all three factors, sclerostin, DKK1,
and RANKL in osteocytes, the most abundant cells in bone, highly ex-
ceeds their expression in osteoblasts (Fig. S4), suggests that osteocytes
are the principal cell target for the anabolic effect of SR10171 on bone.
A potential mechanism underlying the skeletal effects of SR10171
could be modulation of the Wnt/β-catenin signaling pathway. Wnt sig-
naling is crucial to all bone cell types and constitutes a complex commu-
nication network between different components and modes of
signaling (e.g. canonical vs. non-canonical) which operate in the context
of speciﬁc cell types (osteoblast, osteocyte and osteoclast) and bone
marrow milieu (Baron and Kneissel, 2013). It has previously been
established that rosiglitazone inhibits Wnt canonical pro-osteoblastic
and anti-osteoclastic activities in bone, including degradation of β-
catenin and suppression of multiple members of this signaling pathway
(Shockley et al., 2009, Rahman et al., 2012). Here we showed that
SR10171 uncouples Wnt pro-osteoblastic (β-catenin activity; Osx and
Mepe expression) from anti-osteoclastic activities (Opg expression)
and correlated these activities to the distinctive effects on pS112 and
pS273 of PPARγ.
Third, we observed a positive effect of SR10171 on cortical bone
mass, an important skeletal compartment as it represents 80% of skele-
tal mass and is affected by high cortical porosity in T2D (Patsch et al.,
2013), andmost fractures in T2D patients occur in the cortical compart-
ment. Increased cortical thickness in DIO mice treated with SR10171
was associated with extensive activation of the periosteal surface,
whichwas relatively inactive in DIO and lean animals. As such, themag-
nitude of periosteal activation induced by SR10171 (9-fold in DIO vs.
1.5-fold in lean) may explain the positive effect on cortical thickness
in the context of obesity. Although it is unclear at this point whether
these effects result from direct activation of PPARs in periosteal osteo-
blasts, or were mediated through signaling derived from osteocytes,
this observation has clinical relevance since the periosteum actively fa-
cilitates fracture healing. Since T2D patients have impaired fracture
healing in general, understanding periosteal function in response to
treatment with PPAR modulators is essential. Similarly, the role of
PPARα in the maintenance of bone mass is not well understood. It has
been shown that PPARα deﬁciency increased the size of the bone mar-
row cavity, but did not have an effect on cortical thickness (Wu et al.,
2000). Interestingly, two reports demonstrated that PPARα activation
in rodents with ﬁbrates prevented bone loss induced by either estrogen
deﬁciency or TZD treatment, and induced periosteal activity (Still et al.,2008, Syversen et al., 2009). Here, we clearly demonstrate that PPARα is
a negative regulator of sclerostin expression. Recently, anti-sclerostin
antibodies have been described as potential anti-osteoporotic therapies,
thus targeting of PPARα directly in osteocytes may offer alternative
pharmacological possibilities to regulate sclerostin levels.
Interestingly, SR10171 had an anabolic effect on the appendicular
but not the axial skeleton, whereas rosiglitazone had a negative effect
in both skeletal sites. There are several possible explanations for this di-
vergence. Firstly, osteocyteswere shown to be amajor anabolic target of
SR10171. These cells are more abundant in cortical bone of appendicu-
lar skeleton as compared to cortical bone in axial skeleton (Qing et al.,
2012), and they are present at higher density in cortical versus trabecu-
lar bone (Lai et al., 2015). Thus, appendicular skeleton, which mostly
consists of compact bone, may provide for a dominant target of
SR10171 action. Secondly, major differences were observed in marrow
adipose volume between the vertebrae and the long bones when com-
paring rosiglitazone and SR10171 treated mice (Table S1). Increased
marrow adipose volume has been associated with bone loss in several
model systems including rosiglitazone treatedmice.With the exception
of rosiglitazone treated mice, it is difﬁcult to detect adipocytes in the
vertebrae at the age of the mice used here. As such, the adipogenic cell
population in the vertebra may not constitute a sufﬁcient target pool
of cells for SR10171 inverse agonist activity to show an effect. Therefore
suppression of the adipocytic activity in the vertebra may not be able to
increase the pool of potential osteoblasts recruited for bone formation.
Thirdly, discordance between axial and appendicular bonemass is com-
mon with DXA measurements in humans. Moreover, the skeletal re-
sponse to osteoporosis treatment varies by site, suggesting that
determinants of axial bonemassmay differ from those of the appendic-
ular skeleton.
In conclusion, SR10171 represents a polypharmacological PPAR
modulator that is insulin sensitizing and normalizes impaired adipocyte
metabolic function. Unlike the TZDs, SR10171 does not affect metabo-
lism during normal adipose function. Most striking, SR10171 has a pos-
itive effect on bone formation and bone turnover, processes that are
attenuated in diabetes, and that are associated with decreased bone
quality and increased fractures. Determining that SR10171 directly reg-
ulates osteocyte function opens an approach for the development of
anti-osteoporotic therapies targeting both PPARγ (repressive) and
PPARα (activation) in osteocytes, while at the same time improving in-
sulin sensitivity. Finally, PTMs of PPARγmay provide a unifying expla-
nation for the paradox of low bone formation, high bone resorption
and greater fracture risk in T2D.
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